PROVECTUS BIOPHARMACEUTICALS, INC.
PVCTdata completeness 75%23 fiscal years on filei. The business — what you’d actually own
| Figure | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Revenue | — | $989,0421 | $557,7102 | $617,1403 | $336,1083 |
| Net income | −$5.54M4 | −$3.55M5 | −$3.1M6 | −$4.73M7 | −$5.43M7 |
| Operating cash flow | −$1.01M8 | −$3.04M9 | −$2.57M10 | −$3.28M11 | −$3.33M11 |
| Capital expenditure | — | — | — | — | — |
| Free cash flow (derived) | — | — | — | — | — |
| Total debt | — | — | — | — | — |
| Cash & equivalents | $682,98412 | $21,60513 | $76,57614 | $307,44215 | $251,29115 |
| Diluted shares | 408.2M | 419.5M | 419.5M | 419.8M | 420.3M |
Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).
ii. Your slice — ownership made literal
If you owned
shares
Net assets behind them
−$0.15
your share of equity
Profit it earned you last year
−$0.13
Free cash flow it threw off
—
Debt you’d be carrying
—
10 shares is a claim on −$0.15 of net worth that earned you −$0.13 last year.
iii. Is this a good business?
Moat signal · return on equity
— avg · 5y
Not enough data in the filings for a return-on-capital reading.
seeing a moat in the numbers →Management signal · capital allocation
+3% shares · 5y
Share count is up 3% over 5 years — owners have been diluted. Worth asking what they got for it.
reading capital allocation →Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.
iv. What it’s worth — engine v0.1.0
DCF · Growth Exit 10Y
not applicable
only 0 years of FCF (need ≥3) — model not applicable
DCF · Growth Exit 5Y
not applicable
only 0 years of FCF (need ≥3) — model not applicable
Earnings Power Value
not applicable
normalized (5y-median) earnings non-positive — EPV undefined
Graham Number
not applicable
diluted EPS missing or non-positive — Graham Number undefined
Different models answer different questions — which to trust when →
Sources — the receipts
- 10-K · period ending 2022-12-31 · accession 0001493152-24-011699 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2023-12-31 · accession 0001641172-25-000993 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2024-12-31 · accession 0001493152-26-012726 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2021-12-31 · accession 0001493152-23-009563 (NetIncomeLoss)
- 10-K · period ending 2022-12-31 · accession 0001493152-24-011699 (NetIncomeLoss)
- 10-K · period ending 2023-12-31 · accession 0001641172-25-000993 (NetIncomeLoss)
- 10-K · period ending 2024-12-31 · accession 0001493152-26-012726 (NetIncomeLoss)
- 10-K · period ending 2021-12-31 · accession 0001493152-23-009563 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2022-12-31 · accession 0001493152-24-011699 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2023-12-31 · accession 0001641172-25-000993 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2024-12-31 · accession 0001493152-26-012726 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2021-12-31 · accession 0001493152-23-009563 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2022-12-31 · accession 0001493152-24-011699 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2023-12-31 · accession 0001641172-25-000993 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2024-12-31 · accession 0001493152-26-012726 (CashAndCashEquivalentsAtCarryingValue)